Table 3.
Multivariate analysis for overall survival, initial site control and new site control
| Characteristic | HR (95% CI) | P-value |
|---|---|---|
| Overall survival | ||
| Age | 0.99 (0.95–1.02) | 0.451 |
| ECOG | 1.63 (0.69–3.86) | 0.263 |
| >2 brain metastases | 0.53 (0.12–2.25) | 0.388 |
| Active extracranial disease | 3.02 (0.62–14.79) | 0.173 |
| Intracranial Surgery prior to RT | 0.62 (0.24–1.61) | 0.326 |
| Treatment WBRT | 1.39 (0.45–4.22) | 0.566 |
| Initial site control | ||
| Total Dose | 0.69 (0.31–1.55) | 0.372 |
| Treatment WBRT | 1.95 (0.68–5.6) | 0.212 |
| Intracranial Surgery prior to RT | 0.47 (0.16–1.36) | 0.164 |
| New site control | ||
| Total Dose | 3.98 (1.13–14.07) | 0.032* |
| Treatment WBRT | 0.05 (0.01–0.35) | 0.002* |
| Active extracranial disease | 11.4 (1.54–84.52) | 0.017* |
Abbreviations: CI confidence interval, HR hazard ratio, ECOG Eastern Cooperative Oncology group
Statistically significant results indicated by *